ImExHS Limited (ASX:IME)
0.3550
0.00 (0.00%)
Sep 4, 2026, 10:26 AM AEST
ImExHS Revenue
ImExHS had revenue of 15.95M AUD in the half year ending June 30, 2026, with 14.94% growth. This brings the company's revenue in the last twelve months to 31.27M, up 18.81% year-over-year. In the year 2025, ImExHS had annual revenue of 28.97M with 9.17% growth.
Revenue (ttm)
31.27M
Revenue Growth
+18.81%
P/S Ratio
0.62
Revenue / Employee
107.81K
Employees
290
Market Cap
19.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.97M | 2.43M | 9.17% |
| Dec 31, 2024 | 26.54M | 6.65M | 33.44% |
| Dec 31, 2023 | 19.89M | 2.64M | 15.32% |
| Dec 31, 2022 | 17.24M | 3.82M | 28.45% |
| Dec 31, 2021 | 13.43M | 2.44M | 22.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Healius | 1.37B |
| Australian Clinical Labs | 736.15M |
| Monash IVF Group | 269.39M |
| Genetic Signatures | 19.33M |
| Cryosite | 16.70M |
| Microba Life Sciences | 14.76M |
| Genetic Technologies | 9.17M |
| BCAL Diagnostics | 2.55M |
ImExHS News
- 3 days ago - ImExHS Earnings Call Transcript: H1 2026 - Transcripts
- 3 days ago - ImExHS Quarterly report: H1 2026 - Filings
- 3 days ago - ImExHS Earnings release: H1 2026 - Filings
- 3 days ago - ImExHS Slides: H1 2026 - Filings
- 3 months ago - ImExHS Slides: FY 2026 - Filings
- 4 months ago - ImExHS Earnings release: Q1 2026 - Filings
- 6 months ago - ImExHS Earnings Call Transcript: H2 2025 - Transcripts
- 6 months ago - ImExHS Annual report: H2 2025 - Filings